MannKind (MNKD) Trades Lower as Afrezza Scripts Come in Flat Week-Over-Week
Tweet
Share
E-mailGet Alerts MNKD Hot Sheet
Price: $4.19 +0.72%
Rating Summary:
9 Buy, 3 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
9 Buy, 3 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
MannKind (NASDAQ: MNKD) Afrezza weekly prescription were flat week over week at 386 vs 387 prior, according to RBC analyst Adnan Butt, citing data from IMS. New prescriptions declined 3.7% to 262 from 272.
The news sent shares of MannKind lower by 5%
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana (HUM) surges on Q1 beat, reiterated adjusted earnings outlook
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
- Compass Minerals International (CMP) PT Lowered to $15 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst Comments, Short Sales, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
